BRUSSELS - The Anticancer Fund is proud to announce that our managing director, Lydie Meheus, has been appointed by the European Commission as alternate of the Committee for Advanced Therapies (CAT) to represent patients for 3 years. The CAT is one of the seven committees at the European Medicines Agency (EMA) and is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products (ATMP’s) and for following scientific developments in the field.

‘I’m looking forward to assure that patient’s interests are taken into account during developments in this area. The Anticancer Fund wants to stay on top of new cancer treatments in cell and gene therapy, so we can inform cancer patients in need of new therapies properly’, says Lydie Meheus.